-
Sinner reaches Italian Open semis, breaks Masters 1000 winning streak record
-
Germany's Merz calls for more investment, less subsidies in EU budget
-
UK minister quits ahead of possible challenge to Starmer
-
Latvia prime minister resigns over straying Ukraine drones
-
Stocks diverge tracking tech, US-China talks
-
Afghanistan's water crisis worsened last year: UN report
-
Russia pummels Kyiv, killing five and denting peace hopes
-
Stars flying into Cannes in private jets 'obscene', say ex-pilots
-
McIlroy eyeing early charge as PGA Championship begins
-
Arteta seeks goal spree for Premier League title cushion
-
UK PM in peril as potential successors jockey for position
-
US jury awards $49.5 mn damages to Boeing 737 MAX victim's family
-
South Africa court clears way for Zuma's arms graft trial
-
Nobel winner Mukwege warns of predatory US deal for DR Congo
-
UK economy resilient as Mideast war, political risks loom
-
Russia pummels Kyiv, killing three and denting peace hopes
-
Subdued Trump left waiting for 'big hug' from Xi
-
Slot has 'every reason to believe' he will remain as Liverpool boss
-
British PM battles to stay in power amid rebellion
-
Ex-Philippine drug war enforcer flees Senate refuge
-
U2 surprise fans in Mexico City to shoot music video
-
Asia stocks uneven as investors assess high-stakes Trump-Xi talks, AI rally
-
Burberry returns to full-year profit on turnaround plan
-
Spiky, polarising, rarely dull: ups and downs of rugby's Eddie Jones
-
Denmark, Australia in the spotlight in Eurovision second semi
-
Heavy Russian strikes on Kyiv kill one, wound 31
-
Xi warns Trump on Taiwan at Beijing summit
-
Iran war and oil dominate BRICS meet in India
-
Bone appetit: Paris pups lap up treats at dog-centric spots
-
Kohli senses end after roaring back to form with IPL century
-
India bars sugar exports until September
-
Madonna, Shakira, BTS to headline first World Cup final half-time show
-
Japan takes 'half step' toward fixing slow retrial system
-
Honda posts operating loss, first since 1957
-
Madonna, Shakira, BTS to headline World Cup final half-time show
-
A quarter of World Cup games risk searing heat: scientists
-
Six hantavirus cruise passengers head to Australia
-
Suspect detained in Philippine senate gunfire: police
-
Cavs top Pistons in overtime for 3-2 series lead
-
Canadian football ready for World Cup coming out party
-
US court suspends sanctions on UN expert on Palestinians
-
Asia markets mixed as Trump-Xi summit, AI trade dominate
-
'Promised to us': The Israelis dreaming of settling south Lebanon
-
'Rare, meaningful': North Korean football team ventures into South
-
In-form Messi hits brace as Miami win 5-3 at Cincinnati in MLS
-
Historic Swiss solar-powered plane crashes into sea
-
A woman UN leader is 'historical justice,' says Ecuadoran contender for top job
-
Indian pharma fuels Africa's 'zombie drug' and opioid crisis
-
After months of blackout, Iran gives internet to select few
-
Wood urges New Zealand to 'create some history' at World Cup
Biden proposes huge expansion of weight loss drug access
Outgoing US President Joe Biden proposed Tuesday to give millions more Americans access to weight loss drugs -- but Donald Trump's incoming health chief looked set to shoot down the idea.
Under the massive US public health insurance programs Medicare and Medicaid, drugs like Ozempic and Wegovy are, for the most part, only available for overweight people with diabetes or heart disease.
But the White House said Biden wanted to make the game-changing medications widely available as a treatment for obesity itself -- expanding coverage to nearly 7.5 million older and lower-income Americans.
"For too many Americans, these critical treatments are too expensive and therefore out of reach," a White House official said, noting that 42 percent of Americans are obese.
The Department of Health and Human Services said separately in a statement that the "transformative medications" would improve the "health and quality of life for millions of people who have obesity."
The move would benefit 3.4 million Americans with Medicare, which gives health insurance to people mainly aged over 65. It would also help four million people eligible for assistance with Medicaid, which targets lower income residents, officials said.
But the last-gasp plan appears unlikely to survive given that Trump's incoming health secretary, Robert F. Kennedy Jr., has previously spoken out against the use of anti-obesity drugs.
In October Kennedy opposed a separate bill in Congress that would have expanded access to the medications, saying the money needed to do that would be better spent on improving nutrition.
"If we spent about one fifth of that giving good food, three meals a day to every man, woman and child in our country, we could solve the obesity and diabetes epidemic overnight," Kennedy said on Fox News.
- 'So stupid' -
He also accused the Danish makers of Ozempic and Wegovy, Novo Nordisk, of "counting on selling it to Americans, because we're so stupid and addicted to drugs."
Kennedy has attracted major controversy for his anti-vaccine activism and embrace of conspiracy theories -- but some of his proposals for improving American's diets have won praise from health campaigners and lawmakers.
Any plan to increase US public health insurance spending would also likely run foul of Trump's bid to slash government budgets and waste.
Trump said last week as he appointed celebrity TV doctor Mehmet Oz to head Medicare and Medicaid that Oz would "cut waste and fraud" in what he called "our Country's most expensive Government Agency."
The Republican has also named tech tycoon Elon Musk and entrepreneur Vivek Ramaswamy to head a so called "government efficiency" commission to cut costs across government.
Biden has taken a different tack during his sole term in office.
The Democrat has led a major drive to lower the exorbitant cost of US prescription medicines, and his success in forcing pharmaceutical giants to reduce the prices of some became a key plank of his reelection campaign before he dropped out in July.
In July, Biden called on Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs, saying firms must stop "ripping off the American people."
W.Morales--AT